Navigation Links
Neurocrine Biosciences Reports Third Quarter 2008 Results
Date:10/28/2008

is symptoms using several different scales for endometriosis pain. The 6-month results from this study, together with data from the other Phase II studies, will be the basis for securing agreement on a registration plan with the Food and Drug Administration (FDA).

The Company is also currently conducting two additional randomized placebo-controlled Phase II clinical trials. The clinical endpoints for both of these trials are a reduction in pelvic pain associated with endometriosis, utilizing a scale proposed by the FDA. The first Phase II trial includes our selected commercial formulation tablet in two doses, (150 mg and 250 mg); this trial has completed randomization in 155 patients. The Company expects topline results from the first three months of treatment in the first quarter of 2009. The second trial is a four arm comparator trial of two doses of elagolix (150 mg and 250 mg), placebo or leuprolide depot. This trial is being conducted in Central and Eastern Europe. Topline data from this 3-month double-blind trial of approximately 180 patients should be available at the end of the first half of 2009.

Neurocrine is also investigating the potential of certain GnRH antagonists in treating other hormone-dependent diseases in Men's and Women's Health.

Corticotropin Releasing Factor (CRF1) Receptor Antagonists for Anxiety/Depression and IBS

The CRF collaboration between Neurocrine and GSK has identified multiple unique high affinity and selective antagonists for the CRF1 receptor that are currently in clinical development for mood disorders and irritable bowel syndrome (IBS). There are currently three distinct CRF compounds in clinical development that have arisen out of the GSK collaboration. The compound (876008) is in a Phase II "proof of concept" trial to evaluate its safety and efficacy in patients with IBS. Approximately 130 patients meeting established diagnostic criteria for IBS have been entered into this cross-over design trial.
'/>"/>

SOURCE Neurocrine Biosciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Webcast Alert: Neurocrine Announces 3Q 08 Financial Results
2. Neurocrine Biosciences to Present at the Oppenheimer 19th Annual Healthcare Conference
3. Neurocrine Biosciences Announces Conference Call and Webcast to Present Third Quarter 2008 Financial Results
4. Neurocrine Biosciences to Present at the UBS Global Life Sciences Conference
5. Neurocrine Biosciences to Present at Thomas Weisel Healthcare Conference and the NewsMakers in the Biotech Industry Conference
6. Neurocrine Biosciences Reports Second Quarter 2008 Results
7. Neurocrine Biosciences Announces Conference Call and Webcast To Present Second Quarter 2008 Financial Results
8. Neurocrine Biosciences to Present at the 2008 Citi Investment Research Global Health Care Conference
9. Neurocrine Biosciences Announces Conference Call and Webcast to Present First Quarter 2008 Financial Results
10. Neurocrine Biosciences Announces Conference Call and Webcast to Present Fourth Quarter and Year End 2007 Financial Results
11. Neurocrine Announces Appointment of Kevin Gorman, Ph.D., as President and Chief Executive Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)...   SunTrust Robinson Humphrey (STRH) today ... its equity research team in biotechnology and oilfield ... equity research demonstrates our commitment to providing our ... their investment decision making," said Biff Woodruff ... to make significant investments in differentiated content at ...
(Date:8/28/2014)... August 28, 2014 A new ... the world is available from Strategic Consulting, Inc., ... “ Industrial Microbiology Market Review, Fourth Edition: Global ... ” (IMMR—4) tracks and compares microbiology test volumes, ... America, Europe and Asia, and forecasts future volumes ...
(Date:8/27/2014)... Utah (PRWEB) August 27, 2014 Varian ... will expand its current Salt Lake City manufacturing facility ... outside of Utah to ultimately create 1,000 new full ... years. , “Utah is home to hardworking people ... can be credited with Varian’s success in the manufacturing ...
(Date:8/27/2014)... 27, 2014   MSC , a healthcare performance ... announced the appointment of Mary Beth Loesch ... years of experience preparing companies for rapid growth and ... Vice President of Corporate Development and Healthcare. In that ... , as well as corporate strategy and marketing. Previously, ...
Breaking Biology Technology:SunTrust Robinson Humphrey Expands Equity Research in Healthcare and Energy 2SunTrust Robinson Humphrey Expands Equity Research in Healthcare and Energy 32 Billion Industrial Microbiology Tests Conducted for Product Quality and Safety Worldwide 22 Billion Industrial Microbiology Tests Conducted for Product Quality and Safety Worldwide 3Varian Medical Systems Groundbreaking on Facility Expansion Triggers Influx of New Jobs to Salt Lake 2Varian Medical Systems Groundbreaking on Facility Expansion Triggers Influx of New Jobs to Salt Lake 3MSC names Mary Beth Loesch President and CEO 2
... Exchange Symbol: MS , , EDMONTON, July 17 /PRNewswire-FirstCall/ ... the treatment of multiple sclerosis (MS), today announced financial and ... 30, 2009. , "The pivotal phase III MAESTRO-01 trial has ... results from this study within the second half of this ...
... , , COLUMBIA, Md., July 17 ... of DHA, Martek Biosciences (Nasdaq: MATK ), announced today that ... The Food Chain and Animal Health (SCFCAH) of the European Union for ... , This is a significant action that will ...
... Minn., July 17 John H. Wang has been named ... several new Sanford Rose Associates executive search offices opening in ... at CircuLite, Inc. With a 30-year career in the medical ... a natural fit to spearhead the Life Science industry practice ...
Cached Biology Technology:BioMS Medical announces second quarter 2009 results 2BioMS Medical announces second quarter 2009 results 3BioMS Medical announces second quarter 2009 results 4BioMS Medical announces second quarter 2009 results 5BioMS Medical announces second quarter 2009 results 6BioMS Medical announces second quarter 2009 results 7BioMS Medical announces second quarter 2009 results 8BioMS Medical announces second quarter 2009 results 9EU Committee Approves New Food Applications for Martek's life'sDHA(TM) 2EU Committee Approves New Food Applications for Martek's life'sDHA(TM) 3Sanford Rose Associates Opens Minneapolis Office 2
(Date:8/28/2014)...  Privacy Advocate and Senior Staff Attorney at the ... the lineup of biometric and mobile commerce experts set ... Summit in Tampa, Florida on ... include Steven Rahman, Director, Technology and Strategy at Samsung, and ... theme of this year,s event is Mobility at the ...
(Date:8/28/2014)... Access to Research Careers) Program has announced the ... Sports Medicine,s Conference on Integrative Physiology of Exercise ... These awards are meant to promote the entry ... groups into the mainstream of the basic science ... scientists at the American College of Sports Medicine,s ...
(Date:8/28/2014)... WASHINGTON, Aug. 28, 2014A new method for measuring and ... help doctors and researchers better understand how drug abuse ... surgery and tissue engineering, and lead to better treatment ... by a team of researchers from Stony Brook University ... of Health, was published today in The Optical Society,s ...
Breaking Biology News(10 mins):Biometrics UnPlugged Welcomes the Electronic Frontier Foundation's Jennifer Lynch to the Mobility at the Crossroads of Commerce and Privacy Summit 2This is your brain's blood vessels on drugs 2This is your brain's blood vessels on drugs 3
... any battle, sizing up one,s opponent is a critical ... means assessing every nook and cranny of the malicious ... the Center for Biological Research of the Spanish Research ... will take out bacteria at their molecular knees, and ...
... (SWCRF) has awarded 13 collaborative research grants and 3 ... represent a portion of the science grant program at ... this year to cancer research. The grant recipients represent ... cancer cellsa hallmark of the Waxman Foundation. Each ...
... Singapore,s Agency of Science, Technology and Research (A*STAR) have made three ... in top scientific journals Cancer Cell , Nature Cell ... mechanism behind cancer metastasis, suggest why breast cancer cells live as ... and fight cervical cancer. Stopping the spread ...
Cached Biology News:In the ring: Researchers fighting bacterial infections zero in on microorganism's soft spots 2In the ring: Researchers fighting bacterial infections zero in on microorganism's soft spots 3The Samuel Waxman Cancer Research Foundation awards $1.54 million in research grants for 2010-2011 2The Samuel Waxman Cancer Research Foundation awards $1.54 million in research grants for 2010-2011 3A*STAR scientists score 'hat-trick' against cancer 2A*STAR scientists score 'hat-trick' against cancer 3